Umecrine Mood

Umecrine Mood AB was founded in 2006 as a subsidiary to Umecrine AB. The business concept of the company is to develop treatments for the negative mental and physical symptoms in Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Syndrome (PMS) caused by endogenous CNS-active steroids derived from the corpus luteum of the ovary. The company offers a unique and novel treatment principle based on inhibition of GABA-steroid action. The portfolio of the company includes a number of newly discovered lead compounds and a drug candidate that is under clinical investigation.